Funding Opportunities

The Divisions of Chemical, Bioengineering and Environmental Transport (CBET) and Civil, Mechanical, and Manufacturing Infrastructure (CMMI) in the Engineering Directorate of the National Science Foundation (NSF) are partnering with the Center for the Advancement of Science in Space, Inc. (CASIS) to solicit research projects in the fields of tissue engineering and mechanobiology that can utilize the International Space Station (ISS) National Lab to conduct research that will benefit life on Earth. Topics must fit the scope of either the Biomechanics and Mechanobiology Program or the Engineering of Biomedical Systems Program and must address fundamental engineering gaps.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this NOFO will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that translate technology and therapeutic innovations from academic and other non-profit research sectors to the marketplace to advance the development of diagnostic and prevention tools or treatments for musculoskeletal, rheumatic, or skin diseases. It supports late-stage pre-clinical research and development, such as moving products towards regulatory approval for clinical testing or making the new lab technologies more practical to use in a clinical setting. It requires close collaboration between the original developers of these technologies and the SBCs.

The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility

While significant progress has been made in understanding the pathomechanisms of neurodegenerative diseases such as Alzheimer’s, the molecular and cellular mechanisms remain poorly understood. This research project aims to combine the use of a chimeric model, induced pluripotent stem cell (iPSC)-based patient-specific brain organoids, transcriptomics, epigenetics and genetic editing approaches to better understand the molecular and cellular aberrations underlying Alzheimer’s disease pathogenesis.

Bioprinting offers the potential to construct highly complex and patient-specific tissues and organs as well as tissue interfaces. However, one of the major bottlenecks that hinders bioprinting of fully functional tissues and organs is the lack of diverse bioinks that can mimic the dynamic properties of the native tissue. This project aims to investigate materials design strategies to create smart bioinks to address this gap, and to apply these bioinks for printing of fully functional osteochondral tissues. One of the fundamental research questions that they hope to answer revolves around how to instruct stem cells to differentiate spatially within a 3D-bioprinted construct towards osteochondral tissue formation.

Launched in Spring 2021, the Research Catalyst and Innovation (RCI) Program includes four new funding mechanisms totaling more than $1.5 million in annual support. The program infuses funding and fosters increased collaboration to catalyze research and spur innovation across the three University of Michigan campuses.

The Office of Research on Women’s Health (ORWH) works in partnership with the NIH Institutes, Centers and Offices (ICOs), as well as with federal agencies and their offices to ensure that women's health research is an integral part of the larger scientific framework to enhance health and treat disease. The ORWH mission includes strengthening research relevant to diseases, disorders, and conditions that affect women and ensuring that research supported by NIH adequately addresses issues regarding women’s health.

Made possible by the Michigan Economic Development Corporation, University of Michigan’s Innovation Partnerships and U-M Fast Forward Medical Innovation, MTRAC Life Sciences awards offer mid-stage translational funding to enable biomedical researchers from non-profit universities, research institutions, and hospital systems across the state of Michigan to develop innovative technologies with commercial potential. Technologies must at least have an invention disclosure on file with Innovation Partnerships and are anticipated to be 12-24 months from a University “exit” in the form of a license into a start-up company or to an existing revenue-generating company. 

The Pew Scholars Program in the Biomedical Sciences provides funding to young investigators of outstanding promise in science relevant to the advancement of human health. The program makes grants to selected academic institutions to support the independent research of outstanding individuals who are in their first few years of their appointment at the assistant professor level.

The Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on demand organs that do not require immunosuppressive drugs. The goal is to use patient cells or a biobank to quickly produce immune- and blood type-matched replacement organs, such as kidneys, hearts, and livers. If successful, PRINT technology would decrease donor list wait times, reduce the need and cost for immunosuppressive drugs, and make organs and tissues more widely available for patients across the country.

ADAPT aims to bring together researchers in systems biology, bioinformatics, mathematical modeling, and oncology to address the challenge of treating ever-changing metastatic cancer. To meet this goal, the ADAPT program invites proposals to three technical areas. Technical area 1 focuses on therapy recommendation techniques, including multi-modal data fusion, resistant trait modeling, and development of biomarkers to predict drug response. Technical area 2 focuses on a new evolutionary clinical trial that treats patients during multiple therapy lines by discovering emergent resistant traits and therapy biomarkers developed in technical area 1. Technical area 3 unites researchers and clinicians through the creation of a cancer treatment and analysis platform to enable real-time data availability. The goal of the program is to accurately predict which patients will respond to which therapies, improving survival in people with metastatic cancers.

The Engineering of Immune Cells Inside the Body, or EMBODY, program aims to develop an adaptable, low-cost platform where cells in the body are given instructions to adjust their behavior. By moving the creation of specially trained immune cells out of the lab and in vivo, this platform could eliminate the time, cost, and access hurdles faced by traditional immune cell therapy manufacturing.

The ARPA-H Sprint for Women’s Health’s new request for solutions (RFS) funding opportunity seeks unconventional approaches and innovative new avenues to push high-impact biomedical research forward to improve women’s health outcomes. The Sprint for Women’s Health will use two funding tracks to foster transformative research and development efforts. One for early-stage research, or “Spark” solutions and the other for later-stage development, or “LaunchPad” solutions.

As a nonprofit organization, MTF Biologics reinvests to positively affect lives across the globe by offering Allograft Innovation Grants for funding translational and clinical research to advance Allograft Tissue Transplantation and support our mission to Save and Heal Lives. Funding is available for both Allograft Translational Research and Allograft Clinical Research projects. Awarded grants are aimed at advancing allograft tissue transplantation science and patient care. Submitted research projects must utilize allografts or allograft-derived materials, and must have a strong clinical translation component. Clinical areas of interest include: Orthopedics, Spine, Sports Medicine, Plastic & Reconstructive Surgery, Aesthetics, Surgical Soft Tissue Repair and Reconstruction, Wound Care, or other areas which utilize allograft transplant technologies.

To advance the understanding and treatment of Myelodysplastic Syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal hematopoiesis of indeterminate potential (CHIP)), the foundation established the MDS Research Fund (MDSRF).

Notification of acceptance or rejection of abstracts will be e-mailed in April 2024. The final selection of abstracts for presentation and placement of accepted abstracts in the program format will be made by the Program Committee of each regional host.

EGFL6 – a poorly studied stem cell regulatory factor – is known to regulate not only ovarian cancer stem-like cell migration and differentiation but also tumor angiogenesis. However, it remains unclear how EGFL6 impacts the immune system. In this research proposal, the investigators will use genetic and pharmacologic approaches to determine which integrins mediate Egfl6-dependent bone marrow granulocytic and monocytic cell proliferation, migration and their differentiation into myeloid-derived suppressor cell and tumor-associated macrophage phenotypes.

The Advanced Research Projects Agency for Health (ARPA-H) is hosting a hybrid Proposers’ Day in support of a planned solicitation for the Resilient Extended Automatic Cell Therapies (REACT) program. The Proposers’ Day will be held virtually and in-person on November 16, 2023, from 8:30 AM to 5:30 PM Mountain Time (MT) in Denver, Colorado.

MTRAC and Kickstart awards are part of the University of Michigan MTRAC for Life Sciences Innovation Hub, a statewide program that supports translational research projects in life sciences with high commercial potential, opens July 2023.

The National Institutes of Health (NIH) announce the availability of Administrative Supplements to provide Technical and Business Assistance (TABA) Funding to Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awardees. TABA Funding is part of a comprehensive NIH program intended to help small businesses identify and address their most pressing product development needs.

The Michigan Translational Research and Commercialization (MTRAC) for Life Sciences Innovation Hub is a statewide program supporting translational research projects in life sciences with high commercial potential, with the ultimate goal of positively impacting human health. Innovators from all schools at the University of Michigan, other institutions of higher education, non-profit research centers, and hospital systems across Michigan are eligible to submit projects for funding consideration.

What if surgeries fixed problems flawlessly, the first time? Precision Surgical Interventions (PSI) aims to help all surgical procedures reach their intended goal with no errors and no need for re-operation. The program aims to develop solutions to two major surgical problems: tumor edge visualization and critical anatomy visualization.

-

SENS Research Foundation’s strategy to prevent and reverse age-related ill-health is to apply the principles of regenerative medicine to repair the damage of aging at the level where it occurs. We are developing a new kind of medicine: regenerative therapies that remove, repair, replace, or render harmless the cellular and molecular damage that has accumulated in our tissues with time. By reconstructing the structured order of the living machinery of our tissues, these rejuvenation biotechnologies will restore the normal functioning of the body’s cells and essential biomolecules, returning aging tissues to health and bringing back the body’s youthful vigor. SENS Research Foundation regularly funds external research with potential to accelerate the development of rejuvenation biotechnology. Due date: Third Quarter review: by August 1st.

A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care (PFC), human performance optimization, and canine medicine/performance.

ARPA-H has officially launched its first program-specific broad agency announcement (BAA): Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO). NITRO aims to revolutionize care for the 32.5 million Americans suffering from osteoarthritis (OA) through groundbreaking approaches to tissue regeneration. NITRO anticipates that teaming will be necessary to achieve the goals of the program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal to the NITRO BAA. Multiple awards and award types are anticipated under the NITRO BAA. For full program details, please see the linked BAA and additional information below. Those interested in NITRO should read the full BAA and contact ARPA-H at NITRO@arpa-h.gov about joining the program.

The Advanced Research Project Agency for Health (ARPA-H) has released a new announcement for an SBIR solicitation. This solicitation invites proposals in the following areas: 1. ARPA-H 01 – Novel telehealth instruments for assessing pediatric well-being. 2. ARPA-H 02 – Microneedle-based patches and digital patch interfaces for remote and real-time transdermal drug delivery and chronic disease management. 3. ARPA-H 03 – Robotics for autonomous soft tissue surgery. 4. ARPA-H 04 – Intra-operative contrast agents. 5. ARPA-H 05 – Scale-Up: Transition disruptive technologies from proof-of-concept prototypes to commercially scalable and deployable technologies.

The field of biomaterials has grown from a niche within materials science to a robust discipline that has enabled significant biomedical advances. However, a major gap still exists between exciting advances in materials science and tailoring these advances towards biomedical problems.

The FSHD Society offers investigator-initiated research grants to support basic, translational and clinical-based research in facioscapulohumeral muscular dystrophy (FSHD).

Kickstart Awards offer early-stage project funding, enabling biomedical innovators to develop proof of concept for technologies. This award is aimed at enhancing the commercialization potential of technology from any Michigan-based non-profit institution to the point of demonstration of utility and possible inclusion in the MTRAC Life Sciences or other funding programs. Awards, which are up to $42,500, have a cost share requirement. To be eligible for the Kickstart program, an invention disclosure needs to be filed with an innovator's institution.

The Michigan Translational Research and Commercialization for Life Sciences Innovation Hub is a statewide program supporting translational research projects in life sciences with high commercial potential, with the ultimate goal of positively impacting human health. Innovators from all schools at the University of Michigan, other institutions of higher education, non-profit research centers, and hospital systems across Michigan are eligible to submit projects for funding consideration.

-

-

Nominations for the ARPA-H Dash will be accepted through an online portal for review between March 29 and April 7, 2023. Each submission should include a piece of evidence with citation, published after January 1, 2018, a short descriptive title for display in the brackets, identification of which ARPA-H focus area is targeted for transformation, and answers to three questions about the proposed transformation.

The objective of the Janice Wiesman Young Investigator Grant Program is to provide funding to researchers at eligible academic or nonprofit institutions who submit innovative research proposals in the areas of translational, clinical, or applied research. The research should advance the understanding of ATTR amyloidosis, facilitate early diagnosis of patients with ATTR amyloidosis, and/or enhance management of patients with a diagnosis of ATTR amyloidosis. Specifically, this program will support two young investigators, such as current fellows, residents, or junior faculty, annually to promote quality research related to ATTR amyloidosis and to support the development of future researchers and clinicians.

This Funding Opportunity Announcement (FOA) announces the renewal of the NIH Research Evaluation and Commercialization Hub (REACH) program, established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs. Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof-of-concept work and the mentorship in product development and commercialization needed to develop high priority technologies within the NIH’s mission.

OREF, in partnership with the Musculoskeletal Transplant Foundation (MTF Biologics) solicits investigator-initiated research proposals focusing on research in the science of biologic—reconstruction, bone regeneration, transplantation—allografts, including stem cells for graft transplantation.

Given the breadth of the discipline, the PhRMA Foundation’s Translational Medicine Program focuses specifically on novel research that uses the “bedside to bench” approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation seeks research proposals that focus on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management. Applicants should work with clinical collaborators to identify unmet clinical needs. Proposals should integrate innovative technologies, with advanced biological, chemical, diagnostic, and pharmacological sciences and engineering methodologies

The PhRMA Foundation’s Postdoctoral Fellowship in Translational Medicine supports individuals (U.S. and non-U.S. citizens) engaged in a multidisciplinary, collaborative research training program at an accredited U.S. university that will extend their credentials in translational medicine.

The Ruth K. Broad Biomedical Research Foundation, Inc., a support corporation of Duke University, funds research in the neurosciences with a specific focus on investigation that may advance the knowledge or treatment of Alzheimer’s disease. Pilot studies that can lead to conventional funding are preferred, to focus the Foundation’s support on new rather than existing research.

The Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine represents a joint effort to encourage and support postdoctoral or clinical research fellows to conduct highly novel and provocative research in the field of regenerative cancer medicine and to establish a successful career path in this field. Funded research is directly related to the enhancement of the physiology of cancer survivors.

NYSCF is soliciting applications from early career investigators for awards to support translational stem cell research. The aim of this initiative is to support highly innovative, emerging scientists whose pioneering approaches have the potential to transform the field of stem cell research, and that leverage stem cells to advance the understanding and treatment of human disease.

The purpose of this Notice of Special Interest (NOSI) is to promote research focused on the development, adaptation, or integration of innovative biomaterials for cancer biology. The applications of these new materials are expected to enable new insights into basic cancer research.

Career Development grant.

The IADR Osteology Foundation New Investigator Award in Oral Tissue Regeneration is jointly sponsored by the International Association for Dental Research (IADR) and the Osteology Foundation, with funding provided exclusively by the Osteology Foundation.

The PKD Foundation’s principal mission is to support basic, translational and clinical research that will benefit patients with autosomal dominant and autosomal recessive polycystic kidney disease (ADPKD and ARPKD).

The McKnight Scholar Awards are given to exceptional young scientists who are in the early stages of establishing an independent laboratory and research career. The intent of the program is to foster the commitment by these scientists to research careers that will have an important impact on the study of the brain.

The Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center is one of the two national Resource Centers established by the National Institute of Dental and Craniofacial Research (NIDCR)’s Dental Oral and Craniofacial Tissue Regeneration Consortium (DOCTRC) initiative. With the overarching goal of developing clinical trial-ready tissue engineering/ regenerative medicine products and protocols, the DOCTRC initiative is providing funding and resources through the Interdisciplinary Translational Project (ITP) program administered by the two national Resource Centers. The MPWRM Resource Center brings together a multi-disciplinary team of clinicians, engineers, scientists, and technology commercialization and regulatory experts from academia and industry to support the regenerative medicine research community by providing resources and expertise to guide innovations that address unmet clinical needs for the regeneration or restoration of DOC tissues.

Made possible by the Michigan Economic Development Corporation, U-M Innovation Partnerships, and U-M Fast Forward Medical Innovation (FFMI), MTRAC Awards offer mid-stage translational funding to enable biomedical researchers across the state of Michigan to develop innovative technologies with high commercial potential. This award is aimed to enhance the commercial potential of a technology owned by any Michigan-based non-profit. Applicants are anticipated to be 12-24 months from a University “exit” in the form of a license into a start-up company or to an existing revenue-generating company. Technologies must at least have an invention disclosure on file with the Institution’s Technology Transfer Office.

Solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems.

The Lurie Prize in Biomedical Sciences is an award presented by the Foundation for the National Institutes of Health to recognize outstanding achievement by a promising young scientist in biomedical research. The Prize is made possible by a generous gift from philanthropist Ann Lurie.

Applications submitted in response to this FOA are expected to propose planning for a clinical trial that explores and enables the evaluation of the safety and/or efficacy of RM interventions using adult stem cells that are not of embryonic or fetal origin.

The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator-initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells.

The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seek highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project, represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions to widely recognized issues in the development of safe and effective RM therapies.

The Michigan Surgical Innovation Accelerator (MSIA) program was established in 2017 by the Department of Surgery at the University of Michigan to stimulate creativity, engagement, and collaboration amongst surgical faculty interested in biomedical innovation and commercialization. Our mission is to foster, de-risk, and accelerate the development of novel technologies that will improve surgical diseases or the care of surgical patients. To date, several MSIA projects have evolved to clinical trials, filed new patents, and earned external follow-on funding.

The Taubman Institute is seeking to support new or existing teams of scientists to develop novel and impactful approaches to integrate their research programs into the clinic setting. The goal is to perform systematic, multiscale phenotyping to gain insights into individual variation in the susceptibility, progression, course, or outcomes of disease. The institute will partner with investigators to support the development and implementation of their research programs. This will include, but not be limited to, development of a research plan, identification of research partners within and external to U-M, infrastructure and database development, support for clinician and ancillary personnel in the clinic, clinical data collection, biological specimen collection, remote data collection, initiation of research plan, and data analysis.

NIDCR announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in response to infectious and autoimmune diseases of dental, oral, and craniofacial (DOC) tissues.

The ITP program provides one-year grants of up to $300,000 per project (exclusive of indirect costs), with all projects requiring a cost share of more than 10% of the budget (indirect costs to be paid at the federally-negotiated rate of the awardee institution/ company).

Michigan Drug Discovery Project Grants are designed to help researchers navigate the challenges between identifying new biologically active compounds and developing them into clinical candidates. They provide a bridge to significant external grant funding and investments.

The primary objective of this FOA is to support Bioengineering Partnerships with Industry (BPI) to: 1) establish a robust engineering solution to a problem in biomedical research or the practice of medicine; 2) develop a strategic alliance of multi-disciplinary partners, one of which must be an industrial partner, based on a well-defined leadership plan; and 3) realize a specific endpoint and deliverables within 5-10 years based on a detailed plan with a timeline and quantitative milestones.

The National Science Foundation (NSF) Divisions of Chemical, Bioengineering, Environmental and Transport Systems (CBET), Integrative and Organismal Systems (IOS), Molecular and Cellular Biosciences (MCB), and Civil, Mechanical, and Manufacturing Innovation (CMMI) seek proposals that elucidate mechanisms of, and develop strategies to, direct the differentiation of undifferentiated cells into mature, functional cells or organoids.

Directorate for Engineering (ENG) National Science Foundation (NSF), $400,000

The 2022 Planning Committee announces that the Call for Abstracts is open! One of the major barriers to manufacturing cells, tissues, and organs at commercial scale is producing components across the entire manufacturing supply chain to meet clinical demand. Further, minimizing resources to maximize output in a cost effective way is necessary to achieve scale. The thematic focus of this year’s technical summit is Achieving Manufacturing Scale.

NYSCF is soliciting applications from early career investigators for awards to be used for exploring the basic biology and translational potential of stem cells. This career development award provides up to $1.5 million in flexible funding over 5 years. Trialect has launched the science&minds platform at https://scienceandminds.com/ where CLIENTS (Pharma, physicians, and scientists) post projects or consults to collaborate with EXPERTS (academic faculty and fellows, etc.).

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

The research must be in the field of pancreatic diseases. Studies intended to advance knowledge in the areas of pancreatic carcinoma, and all forms of pancreatitis would be the closest to the areas of interest of the NPF.

This funding opportunity announcement (FOA) is designed to support highly integrated research teams of three to six PDs/PIs to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. Applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies, or infrastructure development are not appropriate for this FOA.

The Partnerships for Innovation (PFI) Program within the Division of Industrial Innovation and Partnerships (IIP) offers researchers from all disciplines of science and engineering funded by NSF the opportunity to perform translational research and technology development, catalyze partnerships and accelerate the transition of discoveries from the laboratory to the marketplace for societal benefit.

All PI-eligible faculty from the Ann Arbor, Dearborn, Flint campuses are eligible to apply. Teams must include one lead PI and at least one co-PI from another school/college or unit. Applications must target a new upcoming large-scale funding opportunity at least $5M. Renewals of existing center grants are not eligible.

Research Associate Deans (RADs) from Ann Arbor, Flint and Dearborn campuses are eligible to apply. RADs representing LSA-Social Sciences and Humanities, the College of Engineering and Michigan Medicine (Ann Arbor campus) are eligible to apply in partnership with proposals led by smaller units where programmatically appropriate.

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

We are writing to remind you that the CB and CG programs have been allocated discretionary funds to be used to further strengthen the cancer-related research being pursued by our members over the next year. The goal is to use these funds to stimulate and support new research opportunities, and to fill existing unmet needs of our members. The CB and CG program leaders recently met and discussed several ways in which we plan to use these funds. Please note that allowable budgets for small project funding has been significantly increased and the scope of potential projects has been broadened.

The purpose of the MDRC Mini Pilot/Feasibility (P/F

The Genetics Prize is presented to a leading scientist, or up to three, in recognition of groundbreaking contributions to any realm of genetics research. Beginning in 2001, the Prize – a gold medal and unrestricted $500,000 cash award – has been awarded for fundamental insights in the field of genetics. These may include original discoveries in genetic function, regulation, transmission, and variation, as well as in genomic organization.

Supports highly promising healthcare and academic professionals, in the early years of one’s first professional appointment, to explore innovative questions or pilot studies that will provide preliminary data and training necessary to assure the applicant’s future success as a research scientist.

The Blavatnik National Awards for Young Scientists recognize the United States' most promising faculty-rank researchers in Life Sciences, Physical Sciences & Engineering, and Chemistry. One Blavatnik National Awards Laureate in each disciplinary category will receive $250,000 in unrestricted funds, and additional nominees will be recognized as Finalists.

Applications to the program are made jointly by U.S. and Israeli researchers. No prior collaboration is required, but the synergy between the researchers must be evident. Also, as you might imagine, the BSF is different from a national science foundation, and insists not only on scientific excellence, but also on collaboration between the principal investigators from the two countries. We base our evaluation of the collaboration, first and foremost, on the joint publications that emanated from the grant.

https://venturewell.org/course-program-grants/

Successful applicants might have made significant advances in producing results that were protected as intellectual property and licensed to a commercial entity – for example, proprietary drugs and biologics, diagnostics, therapeutic interventions, health care information technology, or new solutions to biobased production of fuels, chemicals and foods.

The purpose of this notice of funding opportunity (NOFO) is to support research to evaluate the long-term effectiveness of COVID-19 vaccines against symptomatic and asymptomatic infections through long-term follow-up of vaccinated individuals (adults and children) and to assess immune response metrics, symptoms, and the development of asymptomatic infection/viral shedding. Studies should be adequately powered to generate product- and variant-specific vaccine effectiveness estimates and to assess risk factors for vaccine breakthrough, including demographic, immunologic, and virologic risk factors, where possible.

The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees.

The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees.

Innovators developing groundbreaking medical device technologies face a number of challenges along the translational path from bench to bedside. The Blueprint MedTech program is an NIH incubator that aims to address such challenges and support the innovators by accelerating the development of cutting-edge medical devices to diagnose and treat disorders of the nervous system. The mission of the program is to catalyze the translation of novel neurotechnologies from early-stage development to first-in-human clinical studies.

Innovators developing groundbreaking medical device technologies face a number of challenges along the translational path from bench to bedside. The Blueprint MedTech program is an NIH incubator that aims to address such challenges and support the innovators by accelerating the development of cutting-edge medical devices to diagnose and treat disorders of the nervous system. The mission of the program is to catalyze the translation of novel neurotechnologies from early-stage development to first-in-human clinical studies.

Innovators developing groundbreaking medical device technologies face a number of challenges along the translational path from bench to bedside. The Blueprint MedTech program is an NIH incubator that aims to address such challenges and support the innovators by accelerating the development of cutting-edge medical devices to diagnose and treat disorders of the nervous system. The mission of the program is to catalyze the translation of novel neurotechnologies from early-stage development to first-in-human clinical studies.

The NIH Blueprint for Neuroscience Research, with participating NIH Institutes and Centers (ICs), intends to promote the new Blueprint MedTech program by publishing a Funding Opportunity Announcement (FOA) to solicit applications to establish incubator hubs to provide medical device developers (“innovators”) with resources to support development of human-grade prototypes. The FOA intends to utilize the U54 activity code and is expected to be published in Summer 2021 with an expected application due date in Fall 2021.

Research projects may be in any area of translational or clinical cancer research.

Welcome to the Proposal Submission Process for the University of Michigan Medical School’s Michigan Translational Research and Commercialization for Life Sciences Hub (MTRAC Hub). The MTRAC Hub provides resources to support translational projects in the life sciences with high commercial potential. The MTRAC Hub is administered by Fast Forward Medical Innovation and the Office of Technology Transfer at the University of Michigan, with generous sponsorship from the Michigan Economic Development Corporation. This program is open to investigators at any public university, non-profit research center, or health system in the state of Michigan. The MTRAC Hub includes research funding for late-stage translational studies, regulatory guidance, business plan development, and mentorship from industry and investment experts. The MTRAC Hub will be focused on 4 specific market segments, or “verticals”: medical devices, diagnostics, therapeutics, and digital health/IT.

We believe that fundamental advances in life sciences depend upon the training and support of high quality young scientists at a critical point in their career – their postdoctoral training. Our goal is to identify these exceptional young scientists and secure funding for their projects.

Chang Gung Memorial Hospital, Taiwan, and Michigan Medicine are pleased to announce a Request for Proposals (RFP) for joint research projects between faculty collaborators at each respective institution. Up to $100,000 (divided between the co-PIs) is available for projects that advance collaborations between the institutions and likely lead to transformative science and the possibility of future extramural funding.

The Major Research Instrumentation (MRI) Program serves to increase access to multi-user scientific and engineering instrumentation for research and research training in our Nation's institutions of higher education and not-for-profit scientific/engineering research organizations. An MRI award supports the acquisition or development of a multi-user research instrument that is, in general, too costly and/or not appropriate for support through other NSF programs

XLerateHealth's team has a unique depth of knowledge in successfully developing healthcare and life sciences startups. We are enterprise-focused and help early stage healthcare companies validate their business model, build out their commercialization strategy, and get ready to attract funding (both non-dilutive and non-dilutive).

The Michigan George M. O’Brien Kidney Translational Core Center (MKTCC) invites investigators to submit proposals to fund new and innovative research projects – clinical, translational and basic – related to kidney disease through its pilot and feasibility grant program.

The UM Frankel Cardiovascular Center (FCVC) McKay Research Grant Competition is an internal grant funding opportunity specifically designed to help new cardiovascular investigators (Assistant Professor level or below) initiate projects that will lead to extramural funding for basic or clinical research. Fellows please note that you may apply for this grant if you expect to receive a faculty appointment with the University of Michigan by July 1 of the year you apply (funding will be activated only after a faculty appointment has taken place). Grants in the range of $5,000-$50,000 are awarded annually on a competitive basis.

The Frankel Cardiovascular Center (FCVC) M-BRISC Grant Competition is specifically designed to foster innovation and promote collaboration among faculty, staff, clinicians, and scientists to further research at Michigan Medicine in the area of sex differences in cardiovascular disease.

Therapeutic Innovation Fund, offered by the Michigan Center for Therapeutic Innovation (MCTI) and Fast Forward Medical Innovation (FFMI), is a five-year, $2.5 million fund created in 2016 to accelerate the discovery and translation of therapeutic candidates at the University of Michigan.

The University of Michigan has again been invited to submit nominees for the prestigious HHMI Gilliam Fellowship for Advanced Study. This fellowship is awarded to student-mentor pairs and we are able to nominate five such pairs. Prospective fellows must be (i) U.S. citizens, U.S. permanent residents, undocumented childhood arrivals, or undocumented individuals who have been granted temporary permission to stay in the US (DACA), and (ii) from populations excluded from and underrepresented in science because of ethnicity, race, or disability status, or Alumni of the HHMI EXROP program, and (iii) at the appropriate stage of their PhD training.

The MICHR Accelerating Synergy Award is designed to support interdisciplinary research teams in pursuing external multi-component large-scale grants (eg, NIH P01, P30, P50, U24, U54, UM1). Being competitive for large-scale grants requires significant advanced planning, a well-defined and central research theme, strong preliminary data, and a history of partnership among collaborating investigators.

The U-M Injury Prevention Center (IPC) anticipates funding 3-6 one-year exploratory project awards in 2022 that have the greatest potential to advance injury prevention science. Awards will be in the amount of either $25,000 or $50,000 per award, and are expected to have a focus on: a) the development and evaluation of primary prevention strategies, programs, and policies; and/or b) the dissemination, implementation, and translation of evidence-based injury prevention strategies.

This Request for Proposals (RFP) from Cures Within Reach (CWR) is seeking clinical repurposing trials in any disease led by a racial / ethnic minority that is underrepresented in biomedical research (as defined by the NIH; https://grants.nih.gov/grants/guide/notice-files/NOTOD-20-031.html).

Grant proposals may be in the areas of basic biomedical or clinical research and should address key questions regarding the pathogenesis, diagnosis, prevention, or treatment of diabetes, its complications, or related endocrine or metabolic disorders (for example: obesity, metabolic syndrome, counter-regulatory proteins).

DISP proposals should be for two years of support, with total requested funding up to $100,000 direct costs. That is, the combined budgets proposed for all Co-Principal Investigators must not exceed a total of $100,000 for the two-year period.

The Kickstart Awards offer funding up to $42,500, with all awarded projects requiring a cost share from the investigator/institution. Proposals must address a discrete milestone that is critical to the advancement of research to the point of product development. This milestone will increase the commercialization potential of the overall research project to the point where it can be considered a strong candidate for further translational research funding and ultimately commercialization. Examples include in-vivo testing, prototype development, beta development and testing, or drug-candidate pre-clinical work.

We are calling for proposals for the 2021 SVRF that address the following research focus area: Identification and investigation of cardiac developmental pathways and mechanisms to increase fundamental knowledge of heart development; applied, but not limited, to the following areas of interest: Pre- and neonatal physiology Developmental systems biology Remodeling potential and plasticity Mechanical, genetic, and biological factors Cardiogenesis and cell fate Placental and maternal health

JDRF is committed to the development of devices to improve health outcomes in people with type 1 diabetes (T1D). Diabetic ketoacidosis (DKA) is a dangerous acute complication of T1D that is insufficiently addressed or even sometimes exacerbated by current therapeutic options. To fill this gap, JDRF invites applications to develop continuous ketone monitor (CKM) functionality in continuous glucose monitor (CGM) devices to warn users of impending DKA events and allow preventive actions to be taken. Each application may request up to $200,000 per year (including up to 10% indirect costs), for up to two years.

The 2021 Michigan AgBio Innovation Challenge invites researchers at public universities, non-profit research institutes and public hospitals across the state of Michigan to do some real-time opportunity assessment and technology pathfinding in the AgBio market space.

NIST invites Manufacturing USA institutes to propose high-impact projects designed to fund awards for research, development, and testbeds to prevent, prepare for, and respond to coronavirus.

The mission of the Breast Cancer Alliance (BCA) is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure. To promote these goals, we invest in innovative research, breast surgery fellowships, regional education, dignified support and screening for the underserved.

NCI SBIR encourages small businesses developing highly innovative and transformative technologies that have the potential to create new scientific paradigms, establish entirely new and improved approaches to significantly improve cancer research, prevention, detection and care in pediatric and/or rare cancers to apply for the NCI SBIR Innovative Concept Award.

Science & SciLifeLab Prize for Young Scientists Applicants are to submit a 1000-word essay that is judged by an independent editorial team organized by the journal Science. Essays are judged on the quality of research and the applicants’ ability to articulate how their work would contribute to the scientific field. This year’s application period is March 15 – July 15, 2021.

The Young Investigator grant is a three-year award designed to support early career researchers, such as postdoctoral, clinical fellows or instructors, pursuing promising childhood cancer research ideas. These grants aim to cultivate the best and brightest researchers of the future who demonstrate a commitment to a research career in pediatric cancer. A mentor is required, and a career development plan must be included.

Applicants should have a track record of conducting high-quality research and an interest in pursuing a significant shift in their trajectories as researchers. We recognize that early-career researchers are rarely given incentives or support to take measured risks in their work, so this award includes a mentoring component, as well as a supportive academic community.

In this spirit, Baxter's Young Investigator Awards seek to stimulate and reward research applicable to the development of therapies and medical products that save and sustain patients' lives. We invite current graduate students and postdoctoral fellows to submit descriptions of ongoing research. The Baxter Young Investigator Awards program consists of two tiers: first-tier awards include a $3,000 cash prize and an onsite visit to Baxter to present the award-winning research; second-tier awards receive a $500 cash prize. Prizes are granted based on merit of the research.

The BBVA Foundation Frontiers of Knowledge Awards recognize fundamental contributions in a broad array of areas of scientific knowledge, technology, humanities and artistic creation, as listed in point 2 of these call conditions.

The Advanced Postdoctoral Fellowship program is designed to attract qualified and promising health scientists, to provide an opportunity to receive full time research training, and to assist these promising individuals in transitioning from a fellowship to an independent (faculty-level) position. JDRF envisions the 3-year award term as a period in which fellows will receive critical research training that will position them to work at the leading edge of their chosen field. An additional, optional 1-year transition award will further assist fellows to proceed to independent faculty or research appointments and will serve as a bridge between the fellowship and independent competitive research funding.

The American Diabetes Association is requesting applications for research focused on the impact of diabetes on health disparities and, the impact of health disparities on diabetes and its complications. The goal of this RFA is to identify grants of the highest scientific merit, with greatest potential for successful outcomes and most innovative and transformative, for funding. The breakdown of targeted grant types is: Innovative Clinical or Translational Science, Junior Faculty Development and Postdoctoral Fellowship Awards.

These awards support early investigators as they establish independence as diabetes researchers with a focus on health disparities. Refer to the ADA Health Disparities and Diabetes Research Award RFA(link is external) for further details.

The American Medical Association is pleased to announce a request for applications for its Accelerating Change in Medical Education Innovation Grant Program. The program’s $30,000 grants aim to hasten the transformation of medical education by supporting the research, implementation and expansion of key innovations and initiatives developed through the AMA “Accelerating Change in Medical Education” initiative, including: Health systems science Coaching in support of competency development Transitions along the medical education continuum The master adaptive learner model Improving diversity in medical education

One-year grants of up to $300,000 per project; Regenerative medicine/ tissue engineering therapies for dental, oral, and craniofacial applications

Innovator Awards are open to researchers who are developing healthcare innovations that could have a major and measurable impact on human health.

Projects responsive to this solicitation must aim to establish a robustly validated and reproducible set of differentiation design rules, mechanistic models, real-time sensing, control, and quality assurance methods, and integrate them into a workable differentiation strategy. They must deepen our fundamental understanding of how cells develop and differentiate, providing insights into mechanisms, molecular machinery, dynamics, and cell-cell and cell-extracellular matrix (ECM) interactions, and use this understanding to manipulate cells purposefully.

We are pleased to announce a competition for Pre-doctoral and Non-traditional postdoctoral Fellowships in Organogenesis as part of a NIH T32 Training Grant (Training Program in Organogenesis). The goal of the fellowship awards are to provide up to two years of support for outstanding scholars who wish to undertake a research project in the field of organogenesis.

The Training Program in Organogenesis is a University-wide predoctoral and postdoctoral training program that offers a range of fellowships to training grant eligible students. The Training Program in Organogenesis offers federally funded Pre and Postdoctoral fellowships, Non-Traditional Postdoctoral fellowships co-sponsored by the Medical School and Dental School.

The award is presented for outstanding research performed by the applicant as described in a 1,000-word essay.

Precision Health at U-M is a population-based, data-driven strategy that uses advanced tools and technology to consider more information about a patient than has traditionally been examined, such as genetic, lifestyle, and environmental factors. These data are used to discover what influences disease development and progression, which will allow researchers to devise approaches to prevent disease, create novel treatments, and craft a process by which to implement discoveries at the point of care.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease.

The Frankel Innovation Initiative encourages U-M faculty to collaborate with experts at U-M and outside institutions in order to help quickly move early-stage research to results that positively affect human health and save lives.

Michigan Drug Discovery Screening Grants include both funding and scientific support for high-throughput screening of small molecules or natural product extracts with the goal of identifying chemical matter for modulating novel therapeutic targets. At the end of the grant, researchers should have identified and confirmed a set of high-quality hit compounds with the potential to be further developed into tool compounds and therapeutic agents. To be eligible for funding, the proposal must present a clear statement of the scientific hypothesis to be tested, supported by strong target validation or phenotypic data. A prerequisite for funding is a validated screening assay requiring minimal optimization, e.g., translation from 96-well to 384-well format.

The Project Grants will advance projects for which compounds active against the intended biological target have been already identified, as well as projects that can benefit from the combined expertise and capabilities of multiple drug discovery experts. U-M researchers working across all therapeutic areas are eligible for a project grant. Funded projects will be conducted in partnership with Michigan Drug Discovery. Project teams that have already successfully completed a Michigan Drug Discovery supported screening campaign are encouraged to apply for Project Grants. However, prior support through Michigan Drug Discovery is not a prerequisite.

The Catalyst Award aims to support early career faculty (at the Assistant Professor or earlier ranks) in advancing their translational research careers. Applicants should propose a research plan that will help them to generate the data needed to strengthen hypotheses for subsequent extramural applications. We encourage applications for innovative projects at all stages of translation (T1-T4) that use one of the following approaches to research: investigator-initiated research or community-based participatory research (CBPR).

This Funding Opportunity Announcement (FOA) invites applications for Centers of Research Translation (CORT). Overall, a CORT research program should be carried out by a synergistic team of scientists who, through an interdisciplinary team science approach, will address a highly significant translational research challenge in a single or a group of highly-related disease(s) or condition(s) within the mission of the NIAMS.

The Grant supports university-level multidisciplinary scientific studies on viral and bacterial infection-induced cancers. We welcome graduate student and post doctoral scientists from chemistry, pharmacology, biochemistry, engineering, biology, and any related disciplines to apply.

Three innovator awards will be granted with one awarded at the faculty, graduate student, and postdoctoral level, respectively. There will be a fourth award added to recognie a person who is making a difference in the BI community.

The Coulter Program collaboratively works with UM faculty to develop medical device concepts invented at UM and license the related IP rights to medical device companies who complete development and seek FDA approvals. The Coulter Program now requires an LOI prior to receiving an invitation to submit a project proposal. The Coulter Program has two award programs – Enlighten and Evolve. Enlighten Award: Awardees receive direct mentoring from medical device industry experts and outside investors, market, regulatory and IP landscape assessments, and introductions to medical device companies. Program deliverables culminate with product strategic plans. Enlighten awardees will be invited to pitch for Evolve Awards to execute on strategic plans. Evolve Award: Uncover – New product design planning, early prototyping and verification studies. Emerge –Advanced prototype development, FDA interactions, validation studies (bench, animal, human), and partnering meetings with medical device companies.

The SPARC-MDD Partnership Grant provides funding and collaborative support for therapeutics projects led by U-M faculty. Selected projects have the potential to receive the equivalent of up to $1.5 million over a three-year period, including in-kind support in areas such as medicinal chemistry and preclinical development.

This Funding Opportunity Announcement (FOA) aims to support early career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses.

A competition to accelerate artificial kidney development toward human clinical trials. Phase 1 of the Artificial Kidney Prize seeks solutions that enable and advance the functionality, effectiveness, and/or reliability of artificial kidneys.

The Michigan Translational Research and Commercialization (MTRAC) Innovation Hub for Ag & Bio is the first in a series of specialized statewide commercialization programs with in-depth domain expertise in specific areas of research. Translational research funding to accelerate the commercialization of high potential Ag & Bio technology is available to innovators at institutions of higher education, non-profit research centers, and hospital systems throughout Michigan.

In response to a 2017 study from the National Academies of Sciences, Engineering, and Medicine (NASEM), the Engineering Research Centers (ERC) program piloted a planning grant opportunity in 2018. This solicitation is a continuation of this pilot program.

Following a temporary suspension of the request for proposals (RFP) process because of the COVID-19 pandemic, the Joint Institute is pleased to announce the reactivation of the 2020 awards cycle with an emphasis on COVID-related projects. The JI accepts proposals on an annual basis from investigators in any health science discipline working collaboratively across the University of Michigan and Peking University Health Science Center.

The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support 1) research on bioethical issues to develop or support the development of an evidence base that may inform future policy directions, and/or 2) certain efforts to develop or augment bioethics research capacity. Applicants may propose to supplement parent awards focused on bioethics or to add a component related to bioethics to a parent award in which bioethics was not the focus. Note that applications must be within the general scope of the parent award.

Tissue Engineering and Regeneration (TEAM) is an interdisciplinary research-intensive training program for individuals who wish to pursue careers in the oral sciences with a focus in the area of restoration of oral-craniofacial tissues.

The Regenerative Medicine Innovation Project (RMIP) was established by the 21st Century Cures Act to accelerate progress in the field by supporting clinical research on adult stem cells, while promoting scientific rigor and protecting patient safety. This initiative is a trans-NIH effort, in coordination with the Food and Drug Administration (FDA).

The National Institutes of Health (NIH) launched the Rapid Acceleration of Diagnostics (RADxSM) initiative to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. Accurate, fast, easy-to-use, and widely accessible testing is required before the nation can safely return to normal life.

This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices.

The Kickstart Awards offer funding up to $42,500, with all awarded projects requiring a cost share from the investigator/institution. Proposals are reviewed and awarded semi-annually, with due dates on February 1 and August 1. All interested researchers must complete a pre-submission application before submitting a full proposal.